Latest news with #xDRIVE
Yahoo
12-06-2025
- Business
- Yahoo
Private Donors Give $350,000 To Precision Medicine Study for Colorectal Cancer Patients
Ron and Martha Doornink have partnered with Fight CRC to support innovative research focused on tumor profiling metastatic colorectal cancer. Ron and Martha Doornink Quote Springfield, Mo., June 12, 2025 (GLOBE NEWSWIRE) -- Philanthropic support from private donors is what's helping fund a new study focused on advancing precision medicine for metastatic colorectal cancer patients. The Ron and Martha Doornink Foundation is giving $350,000 to help support a feasibility study led by the national nonprofit Fight Colorectal Cancer (Fight CRC) in partnership with biotech company First Ascent Biomedical. The study will utilize First Ascent's xDRIVE tumor profiling platform, which integrates functional drug testing, genetic analysis, and artificial intelligence to deliver rapid, personalized treatment insights. First Ascent's xDRIVE platform enables clinicians to understand tumor biology in real time, providing a clearer path to treatment personalization. Outcomes of the study will lead to increasing understanding and access to a patient's biomarkers, which are unique markers inside a tumor that are essential to identify when it comes to personalizing treatment options. 'Ron and Martha have both been personally impacted by colorectal cancer, which fuels their deep passion for advancing research and improving outcomes for patients facing this disease,' said Anjee Davis, CEO of Fight Colorectal Cancer. 'Their advocacy and support have been instrumental in making this project possible, and we are grateful for their generosity and trust as they team up with Fight CRC to make this happen.' 'We believe in the power of innovation to change lives,' said Ron Doornink, a Fight CRC emeritus board member. 'Supporting this study gives us hope that patients will benefit from more effective, personalized treatment approaches.' The study began enrolling patients in 2025 and will include 25 individuals with metastatic colorectal cancer seen in Rochester, Minnesota. The study is expected to complete enrollment within nine months. Leading the clinical efforts are Hao Xie, MD, PhD, gastrointestinal cancer specialist and precision medicine expert; and Dr. Boardman, a nationally recognized researcher in colorectal cancer. Dr. Boardman previously received a $200,000 research grant from Fight CRC, also supported by the Ron and Martha Doornink Foundation. Noah Berlow, PhD, Chief Technology Officer at First Ascent Biomedical, serves as the study's principal investigator. Additional details will be available on as the study progresses. 'This collaboration with Fight Colorectal Cancer represents an important step toward more precise, timely interventions for patients with advanced disease,' said Jim Foote, founder and CEO of First Ascent Biomedical. This is the 16th research grant Fight CRC has awarded to cutting-edge colorectal cancer research in its 20-year history; several of the awards were privately funded by philanthropists like the Doorninks. To learn more about how to partner with Fight CRC in funding research, contact Michell Baker at PhilTeam@ Attachment Ron and Martha Doornink Quote CONTACT: Savanna Doud Fight Colorectal Cancer 703.548.1225 savanna@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
06-06-2025
- Business
- Business Upturn
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
By GlobeNewswire Published on June 6, 2025, 23:41 IST Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) — First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
06-06-2025
- Health
- Yahoo
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on CONTACT: Savanna Doud Fight Colorectal Cancer 703.548.1225 savanna@ in to access your portfolio
